Document is current
Any future updates will be listed below
-
Authors
Ballatori, Alexander M.
Shahrestani, Shane
Chen, Xiao T.
Ton, Andy
Wang, Jeffrey C.
Buser, Zorica https://orcid.org/0000-0002-5680-0643
- License Information
-
More Information
Article History
Received: 25 May 2021
Revised: 17 September 2021
Accepted: 11 October 2021
First Online: 24 October 2021
Declarations
:
: There are no conflicts of interest in this study. Disclosures outside of submitted work: JCW—Royalties—Biomet, Seaspine, Amedica, Synthes; Investments/Options—Bone Biologics, Pearldiver, Electrocore, Surgitech; Board of Directors—AO Foundation, Fellowship Funding (paid to institution): AO Foundation. ZB—consultancy: Cerapedics (past), The Scripps Research Institute (past), Xenco Medical (past), AO Spine (past); Research Support: SeaSpine (past, paid to the institution), Next Science (paid directly to institution), Medical Metrics (past, paid directly to institution); North American Spine Society: committee member; Lumbar Spine Society: Co-chair Educational Committee, AOSpine Knowledge Forum Degenerative: Associate member; AOSNA Research committee- committee member.
: Not applicable.
: Not applicable.
: The data source (Healthcare Cost and Utilization Project National Readmission Database) is de-identified, and therefore this study was exempt from institutional review board approval.
: Not applicable.
: Not applicable.
